Home
|
Inbox
|
Search
|
View Abstract
Macrolides for the Treatment of Asthma - An Updated Systematic Review and Meta-Analysis
Description
.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px } .abstract { overflow-x:scroll } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px } .abstract td, th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; } .abstract a { overflow-wrap: break-word; word-wrap: break-word; }
A1086 - Macrolides for the Treatment of Asthma - An Updated Systematic Review and Meta-Analysis
Author Block: F. Wang1, X. Tang1, L. Sun1, C. Wei1, W. Zhu1, H. Liu1, L. Xu1, H. Mao1, F. Luo2; 1West China Hospital, Sichuan University, Chengdu, China, 2West China Hospital, Chengdu Sichuan 610041, China.
Rationale: Researches have showed that macrolides are antibiotics which have anti-microbic and immunemodulatory effects on asthma. However, results from clinical trials have been contentious. We sought to conduct a meta-analysis of clinical trial results to update the current evidence of macrolides in the management of patients with asthma.
Methods: Randomized controlled trials (RCTs) of macrolides treatment on patients with asthma published up to October 2017 in PubMed, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) that reported pulmonary function, quality of life scores, symptom scores, asthma control were included. The pooled standard mean difference (SMD) or mean differences (MD), and 95% confidence intervals (CIs) were calculated using fixed- or random-effects models.
Results: Sixteen studies involving 1745 patients were identified. Our analysis showed that macrolides treatment could significantly improve asthma control (SMD=-0.58, 95% CI: -1.15 to -0.01), quality of life (MD=0.16, 95% CI: 0.04 to 0.29), symptom scores (MD=-0.76, 95% CI: -1.29 to -0.23), but was not also associated with improvement in FEV1 (first second forced expiratory volume) (SMD=0.06, 95% CI: -0.06 to 0.28) and PEF (peak expiratory flow) (MD=0.11, 95% CI: -0.02 to 0.24).
Conclusions: Macrolides treatment seemed to have no effect on lung function (FEV1 or PEF), but produced significant improvements in asthma control, quality of life, and symptom scores. Further large clinical trials are necessary to measure the clinically relevant outcomes (ie, asthma exacerbations, symptom score, lung function).
Author Block: F. Wang1, X. Tang1, L. Sun1, C. Wei1, W. Zhu1, H. Liu1, L. Xu1, H. Mao1, F. Luo2; 1West China Hospital, Sichuan University, Chengdu, China, 2West China Hospital, Chengdu Sichuan 610041, China.
Rationale: Researches have showed that macrolides are antibiotics which have anti-microbic and immunemodulatory effects on asthma. However, results from clinical trials have been contentious. We sought to conduct a meta-analysis of clinical trial results to update the current evidence of macrolides in the management of patients with asthma.
Methods: Randomized controlled trials (RCTs) of macrolides treatment on patients with asthma published up to October 2017 in PubMed, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) that reported pulmonary function, quality of life scores, symptom scores, asthma control were included. The pooled standard mean difference (SMD) or mean differences (MD), and 95% confidence intervals (CIs) were calculated using fixed- or random-effects models.
Results: Sixteen studies involving 1745 patients were identified. Our analysis showed that macrolides treatment could significantly improve asthma control (SMD=-0.58, 95% CI: -1.15 to -0.01), quality of life (MD=0.16, 95% CI: 0.04 to 0.29), symptom scores (MD=-0.76, 95% CI: -1.29 to -0.23), but was not also associated with improvement in FEV1 (first second forced expiratory volume) (SMD=0.06, 95% CI: -0.06 to 0.28) and PEF (peak expiratory flow) (MD=0.11, 95% CI: -0.02 to 0.24).
Conclusions: Macrolides treatment seemed to have no effect on lung function (FEV1 or PEF), but produced significant improvements in asthma control, quality of life, and symptom scores. Further large clinical trials are necessary to measure the clinically relevant outcomes (ie, asthma exacerbations, symptom score, lung function).
|
Home
|
Inbox
|
Search
|